Compositions comprising modafinil for treatment of fatigue associated with multiple sclerosis
CA 2689735 A1 · Owner: Miller, Matthew S. · Inventors: Miller, Matthew S.; Scammell, Thomas E.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Modafinil is effective in improving symptoms of attention deficit hyperactivity , disorder and symptoms of multiple sclerosis fatigue. The administration of modafinil is , also shown to activate the tuberomamillary neurons of the posterior hypothalamus, and , thus exhibits activity in an area of the brain associated with normal wakefulness, functions. A method of identifying a compound that selectively modulates activity of the , tuberomamillary nuclues of the posterior hypothalamus is also disclosed.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 16, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended August 16, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 16, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.